Alejandro M. Hortal

Madrid, MD 28049, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications

Antigen receptor ITAMs provide tonic signaling by acting as guanine nucleotide exchange factors to directly activate R-RAS2.

Antigen receptor ITAMs provide tonic signaling by acting as guanine nucleotide exchange factors to directly activate R-RAS2.

Journal: Science signaling
Published: January 28, 2025

The R-RAS2 GTPase is a signaling hub in triple-negative breast cancer cell metabolism and metastatic behavior.

The R-RAS2 GTPase is a signaling hub in triple-negative breast cancer cell metabolism and metastatic behavior.

Journal: Journal of hematology & oncology
Published: December 19, 2024

Unmutated RRAS2 emerges as a key oncogene in post-partum-associated triple negative breast cancer.

Unmutated RRAS2 emerges as a key oncogene in post-partum-associated triple negative breast cancer.

Journal: Molecular cancer
Published: February 15, 2024

Characterization of Three Somatic Mutations in the 3'UTR of RRAS2 and Their Inverse Correlation with Lymphocytosis in Chronic Lymphocytic Leukemia.

Characterization of Three Somatic Mutations in the 3'UTR of RRAS2 and Their Inverse Correlation with Lymphocytosis in Chronic Lymphocytic Leukemia.

Journal: Cells
Published: October 25, 2023

Mice Overexpressing Wild-Type RRAS2 Are a Novel Model for Preclinical Testing of Anti-Chronic Lymphocytic Leukemia Therapies.

Mice Overexpressing Wild-Type RRAS2 Are a Novel Model for Preclinical Testing of Anti-Chronic Lymphocytic Leukemia Therapies.

Journal: Cancers
Published: September 19, 2023

An Optimized Single Nucleotide Polymorphism-Based Detection Method Suggests That Allelic Variants in the 3' Untranslated Region of RRAS2 Correlate with Treatment Response in Chronic Lymphocytic Leukemia Patients.

An Optimized Single Nucleotide Polymorphism-Based Detection Method Suggests That Allelic Variants in the 3' Untranslated Region of RRAS2 Correlate with Treatment Response in Chronic Lymphocytic Leukemia Patients.

Journal: Cancers
Published: November 30, 2022

Overexpression of wild type RRAS2, without oncogenic mutations, drives chronic lymphocytic leukemia.

Overexpression of wild type RRAS2, without oncogenic mutations, drives chronic lymphocytic leukemia.

Journal: Molecular cancer
Published: October 08, 2021

A hotspot mutation targeting the R-RAS2 GTPase acts as a potent oncogenic driver in a wide spectrum of tumors.

A hotspot mutation targeting the R-RAS2 GTPase acts as a potent oncogenic driver in a wide spectrum of tumors.

Journal: Cell reports
Published: September 17, 2021
Showing 1-8 of 8

Last Updated: 09/26/2026